Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower Income Countries Through COVAX

11/23/2021 | 08:09am EST

Johnson & Johnson (the Company) welcomes the decision of EU Member States along with Norway and Iceland (Team Europe) to donate almost 100 million doses of its COVID-19 vaccine through the COVAX Facility. As a practical rapid response to the urgent need to scale up equitable access to vaccines, these doses will be utilized to help protect individuals in lower-income countries.

Supported by the European Commission, Team Europe are providing these doses under an agreement signed recently by the Government of Belgium (acting on behalf of Team Europe), Gavi, The Vaccine Alliance (GAVI) and Johnson & Johnson. The agreement will enable doses of the Company's vaccine to be shipped directly to COVAX for the benefit of low- and middle-income countries through the remainder of this year and into early 2022.

'We welcome the leadership shown by the European Commission and Team Europe in transferring these doses to accelerate COVID-19 vaccination in lower income countries and to help address the global vaccine equity challenge,' said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer. 'We will continue to support governments that have doses of our vaccine to share, particularly through the COVAX Facility as we believe that it is an essential mechanism to help combat the pandemic globally.'

At a time when only 4.7 percent[1] of people in low-income countries have received at least one dose of a COVID-19 vaccine, a global effort is needed to support the WHO's goals of reaching 40 percent global vaccine coverage by the end of this year, and 70 percent of people everywhere by mid-2022.[2]

Recipient countries are determined by Gavi, who together with Alliance partners UNICEF and WHO, will work alongside receiving governments on country readiness and the transfer of these doses. The Company will provide certain supply chain and logistical support to ensure donated vaccines can be delivered to recipient countries as quickly as possible, and we are proud to be working with governments and Gavi to make this happen. First shipments of doses will begin arriving in a number of African countries this week.

The Company has committed to providing its vaccine on a not-for-profit basis globally for emergency pandemic use and is making available up to 500 million doses of its vaccine to the COVAX Facility through 2022. This is in addition to donations by the EU and others of the Johnson & Johnson vaccine.

About COVAX [3]

COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by CEPI, Gavi and WHO - working in partnership with developed and developing country vaccine manufacturers, UNICEF, PAHO, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both high-income and lower-income countries.

Notice to Investors Concerning Forward-Looking Statements

This media statement contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development, manufacture and distribution of our COVID-19 vaccine. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


[1] Our World in Data, Coronavirus (COVID-19) vaccinations. Available at: https://ourworldindata.org/covid-vaccinations. Last accessed: 16 November 2021

[2] WHO, UN set out steps to meet world COVID vaccination targets. Available at: https://www.who.int/news/item/07-10-2021-who-un-set-out-steps-to-meet-world-covid-vaccination-targets#:~:text=The%20new%20strategy%20outlines%20a,70%25%20by%20mid%2D2022. Last accessed: November 2021

[3] COVAX working for global equitable access to COVID-19 vaccines. Available at: https://www.who.int/initiatives/act-accelerator/covax. Last accessed: November 2021

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
08:46aJohnson & Johnson Statement on New Mexico Opioid Settlement Agreement
03:02aMidatech Pharma, Janssen Extend R&D Partnership On Experimental Medicine
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
01/13Divco West Real Estate Services, LLC acquired 143,000 square feet, 5000 Shoreline Court..
01/12Johnson & Johnson's COVID-19 Vaccine Fact Sheet Updated to Include Risk of Rare Bleedin..
01/12South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Booster..
01/11US FDA Adds Risk of Rare Bleeding Disorder to Johnson & Johnson COVID-19 Jab's Fact She..
01/11Mix and Match Covid-19 Vaccine Study to Take Place in Mozambique
01/10Johnson & Johnson Mulls Inorganic Opportunities
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 306 M - -
Net income 2021 22 542 M - -
Net Debt 2021 596 M - -
P/E ratio 2021 19,9x
Yield 2021 2,47%
Capitalization 442 B 442 B -
EV / Sales 2021 4,69x
EV / Sales 2022 4,37x
Nbr of Employees 134 500
Free-Float -
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 167,84 $
Average target price 183,50 $
Spread / Average Target 9,33%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%218 444